// App-Quantinova.ai

4861 : Oral immune checkpoint antagonists targeting PD-L1/VISTA or PD-L1/Tim3 for cancer therapy

Researchers

Presenter

  • Pottayil Sasikumar

Principal Investigators

  • N S Sudarshan

  • Nagaraj Gowda

  • D S Samiulla

  • Raghuveer Ramachandra

  • T Chandrasekhar

  • Sreenivas Adurthi

  • Jiju Mani

  • Rashmi Nair

  • Sharad Singh

  • Amit Dhudashia

  • Nagesh Gowda

  • Murali Ramachandra

Medical Centers

  • Aurigene Discovery Technologies Ltd, Bangalore, India

Locations

  • India

Companies

  • Aurigene Discovery T

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

  • Cytotoxic T-lymphocyte-associated protein 4

Drug/Treatment

  • Vista

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved